TY - JOUR
T1 - Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in Children with Autism Spectrum Disorder
AU - Scahill, Lawrence
AU - Bearss, Karen
AU - Sarhangian, Rena
AU - McDougle, Christopher J.
AU - Arnold, L. Eugene
AU - Aman, Michael G.
AU - McCracken, James T.
AU - Tierney, Elaine
AU - Gillespie, Scott
AU - Postorino, Valentina
AU - Vitiello, Benedetto
N1 - Funding Information:
This study was supported by funds under contracts N01MH80011 (Dr. Aman), N01MH70001 (Dr. McDougle), N01MH70010 (Dr. McCracken), and N01MH70009 (Dr. Scahill) from the National Institute of Mental Health, Bethesda, Md, by grants M01 RR00750 for Indiana University, Indianapolis, M01RR00052 for Johns Hopkins University, Baltimore, MD, M01 RR00034 for The Ohio State University, Columbus, and M01 RR06022 for Yale University, New Haven, Connecticut, from the General Clinical Research Centers, National Center for Research Resources, National Institutes of Health, Bethesda, by grants K23 MH068627 (Dr. Posey) and K24 MH001805 (Dr. McCracken) from the National Institute of Mental Health, and by the Korczak Foundation, Amsterdam, the Netherlands (Dr. Scahill). The study was also supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1 TR000454 (Emory University) and the Marcus Foundation.
Publisher Copyright:
© Copyright 2017, Mary Ann Liebert, Inc. 2017.
PY - 2017/3
Y1 - 2017/3
N2 - Objectives: Parent rating scales are commonly used to evaluate change in clinical trials. Despite advantages, these measures may not capture parental impression of the child's most salient problems. We examine the use of parent target problems (PTPs) in a randomized trial of methylphenidate (MPH) in children with autism spectrum disorder and symptoms of attention-deficit/hyperactivity disorder. Methods: This multisite, 4-week, randomized crossover trial compared three dose levels (low, medium, and high) of MPH with placebo. At baseline, the independent evaluator (IE) asked parents to nominate the child's two biggest problems. For each problem, the IE and parent coconstructed a brief narrative of the behavior and the impact on family life. The IE and parents reviewed and revised the narratives at subsequent visits. A panel of four judges, blind to treatment condition, independently reviewed the narratives to rate change from baseline on a 9-point scale: 1, normal; 2, markedly improved; 3, definitely improved; 4, equivocally improved; 5, no change; 6, possibly worse; 7, definitely worse; 8, markedly worse; 9, disastrously worse. The mean of the four raters was compared with primary and key secondary ratings from the original study. Results: Two PTPs were recorded at baseline for 60 participants. The inter-rater reliability of the four judges across all PTPs and time points was excellent (intraclass correlation = 0.95). On the primary outcome measure (Aberrant Behavior Checklist Hyperactivity subscale), the medium and high-dose levels were superior to placebo. On the mean PTP rating, only the high dose was superior to placebo. We also compared PTP cutoff scores 3.0 (definitely improved), 3.25, and 3.5 with the rate of positive response on the Improvement item of the Clinical Global Impressions scale in the original study. Sensitivities ranged from 68% to 88%. Conclusions: The parent target problem method offers a systematic way to identify and track patient-centered outcomes.
AB - Objectives: Parent rating scales are commonly used to evaluate change in clinical trials. Despite advantages, these measures may not capture parental impression of the child's most salient problems. We examine the use of parent target problems (PTPs) in a randomized trial of methylphenidate (MPH) in children with autism spectrum disorder and symptoms of attention-deficit/hyperactivity disorder. Methods: This multisite, 4-week, randomized crossover trial compared three dose levels (low, medium, and high) of MPH with placebo. At baseline, the independent evaluator (IE) asked parents to nominate the child's two biggest problems. For each problem, the IE and parent coconstructed a brief narrative of the behavior and the impact on family life. The IE and parents reviewed and revised the narratives at subsequent visits. A panel of four judges, blind to treatment condition, independently reviewed the narratives to rate change from baseline on a 9-point scale: 1, normal; 2, markedly improved; 3, definitely improved; 4, equivocally improved; 5, no change; 6, possibly worse; 7, definitely worse; 8, markedly worse; 9, disastrously worse. The mean of the four raters was compared with primary and key secondary ratings from the original study. Results: Two PTPs were recorded at baseline for 60 participants. The inter-rater reliability of the four judges across all PTPs and time points was excellent (intraclass correlation = 0.95). On the primary outcome measure (Aberrant Behavior Checklist Hyperactivity subscale), the medium and high-dose levels were superior to placebo. On the mean PTP rating, only the high dose was superior to placebo. We also compared PTP cutoff scores 3.0 (definitely improved), 3.25, and 3.5 with the rate of positive response on the Improvement item of the Clinical Global Impressions scale in the original study. Sensitivities ranged from 68% to 88%. Conclusions: The parent target problem method offers a systematic way to identify and track patient-centered outcomes.
KW - Autism spectrum disorder
KW - Double-blind method
KW - Methylphenidate
KW - Patient-centered outcomes
UR - http://www.scopus.com/inward/record.url?scp=85016111808&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016111808&partnerID=8YFLogxK
U2 - 10.1089/cap.2016.0107
DO - 10.1089/cap.2016.0107
M3 - Article
C2 - 27893955
AN - SCOPUS:85016111808
SN - 1044-5463
VL - 27
SP - 125
EP - 131
JO - Journal of child and adolescent psychopharmacology
JF - Journal of child and adolescent psychopharmacology
IS - 2
ER -